

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7458330

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
ALIREZA REZANIA	07/22/2022
VALENTIN SLUCH	07/22/2022
JASON SAGERT	07/22/2022
RECEIVING PARTY DATA	
Name:	CRISPR THERAPEUTICS AG
Street Address:	BAARERSTRASSE 14
City:	ZUG
State/Country:	SWITZERLAND
Postal Code:	6300
PROPERTY NUMBERS Total: 4	
Property Type	Number
Application Number:	17538566
Application Number:	63250048
Application Number:	63214134
Application Number:	63119512
CORRESPONDENCE DATA	
Fax Number:	(720)489-3779
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	303-572-9300
Email:	kschwalbach@polsinelli.com
Correspondent Name:	POLSINELLI PC
Address Line 1:	1401 LAWRENCE STREET
Address Line 2:	SUITE 2300
Address Line 4:	DENVER, COLORADO 80202
ATTORNEY DOCKET NUMBER:	100867-706145 (CT150-US1)
NAME OF SUBMITTER:	KATIE SCHWALBACH
SIGNATURE:	/Katie Schwalbach/
DATE SIGNED:	07/28/2022

Total Attachments: 4

source=Executed_Assignment#page1.tif

source=Executed_Assignment#page2.tif

source=Executed_Assignment#page3.tif

source=Executed_Assignment#page4.tif

ASSIGNMENT BY INVENTORS

The undersigned Assignor Alireza Rezania, Valentin Sluch, and Jason Sagert, for good and valuable consideration paid to us by

CRISPR THERAPEUTICS AG

a Corporation of Zug, Switzerland, having its principal place of business at Baarerstrasse 14, 6300 Zug, Switzerland, the receipt and sufficiency of which is hereby acknowledged, do hereby sell, assign, transfer and set over unto said

CRISPR THERAPEUTICS AG

its successors, legal representatives and assigns, the entire right, title and interest for the United States of America and all jurisdictions worldwide including all rights of priority under the Paris Convention for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the jurisdiction in which any such protection is sought in connection with subject matter including the invention or improvement in

GENE-EDITED NATURAL KILLER CELLS

described in applications, in any form or embodiment thereof

- ☒ U.S. Application No. 63/250,048, filed on September 29, 2021
- ☒ U.S. Application No. 63/214,134, filed on June 23, 2021
- ☒ U.S. Application No. 63/119,512, filed on November 30, 2020
- ☒ U.S. Application No. 17/538,566, filed on November 30, 2021

in the United States Patent and Trademark Office, and in all Letters Patent of the United States and all jurisdictions worldwide which may or shall be granted on or otherwise directed to said invention, or any equivalent or parts thereof or improvements now or hereafter made, or on said application, or any continuing, divisional, extension, provisional, reexamination, reissue, renewal, substitute, supplemental examination or other applications based in whole or in part thereon, and all rights to seek compensation for past infringement of said invention worldwide. And I agree, for myself and my executors and administrators, with said Corporation and its successors and assigns but at its or their expense and charges, hereafter to execute all applications, amended specifications, deed or other instrument, and to do all acts necessary or proper to secure the grant of Letters Patent in the United States and in all other countries to said Corporation, with specifications and claims in such form as shall be approved by the counsel of said Corporation and to vest and confirm in said Corporation, its successors and assigns, the legal title to all such patents.

And Alireza Rezania, Valentin Sluch, and Jason Sagert do hereby authorize CRISPR THERAPEUTICS AG to file, or forego filing, patent applications in any jurisdictions worldwide on said invention in the name of the Assignee.

And Viktorria Kyrychenko, Alireza Rezaia, Valentin Sluch, and Jason Sagert hereby authorize the Commissioner of Patents of the United States and any authority of any jurisdiction whose duty it is to issue protections on inventions as aforesaid, to issue such Letters Patent as shall be granted upon said application or applications based thereon to said Corporation, its successors, legal representatives and assigns, the same to be held by Assignee for its own use and benefit and the use and benefit of its successors, legal representatives and assigns to the full end of the term or terms for which Letters Patents may be granted and/or extended.


And Alireza Rezaia, Valentin Sluch, and Jason Sagert hereby represent and covenant that, at the time of execution and delivery of this instrument, except for any rights, titles and interests that have arisen to Assignee under law or that have already been transferred to Assignee, Andrew Richard Dunn is the sole and lawful owner of the entire right, title and interest in and to the said inventions above-mentioned, and that the same are unencumbered and that I have good and full right and lawful authority to convey the same to Assignee in the manner herein set forth, and that Andrew Richard Dunn has not executed, and will not execute, any instrument in conflict herewith.

And Alireza Rezaia, Valentin Sluch, and Jason Sagert further hereby agree that should any provision of this Assignment be determined to be void, invalid, unenforceable or against public policy, such provision may be altered in time or scope in order to give effect to such provision. If such alteration is not possible, such provision shall be deemed as severed from this Assignment and the remainder of this Assignment shall remain in full force and effect, so long as the original intent of this Assignment remains substantially intact.

This Assignment shall be interpreted and construed according to, and governed by, the laws of Zug, Switzerland.

In witness whereof, Alireza Rezaia, Valentin Sluch, and Jason Sagert and CRISPR THERAPEUTICS AG hereunto set this Assignment to be executed, and agree to be legally bound thereby, as of the dates indicated below.

Date: 22-Jul-22

Signed: DocuSigned by:

E87583CEE9F440C...
ALIREZA REZANIA

Date: 22-Jul-22

Signed: DocuSigned by:

8CD85E61DDD342D...
VALENTIN SLUCH

Date: 22-Jul-22

Signed: DocuSigned by:

75279B4E2A53413...
JASON SAGERT

ASSIGNEE:

I hereby acknowledge that rights in the above-identified application(s) have transferred from the Assignor(s) by virtue of their above execution of this Assignment and are hereby conveyed to CRISPR THERAPEUTICS AG, the Assignee, of which I am an authorized signatory.

Date: 27-Jul-22

Signed: Anders Kassow
SIGNATORY NAME

DocuSigned by:
Anders Kassow
6F4774054302475
SIGNATORY TITLE

CRISPR THERAPEUTICS AG